MaxCyte Share News (MXCT)

IN BRIEF: MaxCyte first-quarter loss narrows; raises annual guidance

MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Says is pleased with positive start to 2022 with "very strong" first-quarter results. For three months to March 31, posts net loss USD4.1 million, narrowed from USD7.1 million last year on revenue of USD11.6 million, up 78% from USD6.5 million. Generates total of USD2.0 million in Strategic Platform License program-related revenue in the first quarter of 2022, compared to immaterial SPL program-related revenue in the first quarter of 2021. For 2022, expects core business revenue to grow at least 25% compared to 2021 core business revenue. It also continues to expect SPL program-related revenue to be around USD4 million in 2022.

MaxCyte reports good first quarter revenue growth

(Sharecast News) - Cell engineering technology company MaxCyte reported total first quarter revenue of $11.6m (£9.42m) in an update on Tuesday - an increase of 78% year-on-year.

TRADING UPDATES: BlueRock output rises; Watkin Jones profit to fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

MaxCyte CFO resigns, first quarter revenues rise

(Sharecast News) - Cell engineering company MaxCyte announced on Wednesday that Amanda Murphy has resigned from her position as chief financial officer as of 15 April, to "pursue other interests".

MaxCyte widens net loss in 2021 while annual revenue increases

(Alliance News) - MaxCyte Inc on Wednesday posted a widened net loss of USD19.1 million in 2021, increased from a loss of USD11.8 million the year before.

MaxCyte reports record Q4 and full-year revenue

(Sharecast News) - Cell engineering company MaxCyte reported record quarterly revenue of $10.2m (£7.73m) for the final three months of 2021 on Wednesday, up 19% year-on-year.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: MaxCyte hires chief scientist from Stemson Therapeutics

MaxCyte Inc - Maryland-based platform for cell-based research - Hires Cenk Sumen as chief scientific officer. Sumen joins from San Diego, California-based hair-loss treatment firm Stemson Therapeutics Corp, where he was chief technology officer.

MaxCyte taps Cenk Sumen as its chief scientific officer

(Sharecast News) - Cell engineering company MaxCyte announced the appointment of Cenk Sumen as its chief scientific officer on Thursday.

MaxCyte to consolidate its restricted and unrestricted shares

(Sharecast News) - Cell engineering technology company MaxCyte announced the consolidation of the two lines of its common stock into a single unrestricted line of common stock on Monday.

MaxCyte signs platform licence with biotech firm Intima

(Sharecast News) - Cell engineering platform technology company MaxCyte announced the signing of a strategic platform licence (SPL) with Intima Bioscience on Tuesday.

MaxCyte signs strategic platform pact with Intima Bioscience

MaxCyte signs strategic platform pact with Intima Bioscience

MaxCyte expects improved full-year revenue on organic growth

MaxCyte expects improved full-year revenue on organic growth

MaxCyte ends year with strong trading

(Sharecast News) - Cell engineering company MaxCyte said on Monday that it expected total revenue for its fourth quarter to be at least $10m, up from $8.5m year-on-year, reflecting growth of at least 17% in total revenue and at least 37% in core business revenue.

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days